Insider · CIK 0001326916
Guy L Smith
Files at IDN (Intellicheck, Inc.). First filing Nov 15, 2023, latest Nov 25, 2025.
In brief
Guy L Smith files SEC Form 4 as director at IDN (Intellicheck, Inc.). Since Nov 15, 2023, Guy L Smith has reported 3 open-market buys worth $17k and 0 open-market sells worth $0, the latest filed on Nov 25, 2025.
A track record needs three past buys with six months of prices behind them; Guy L Smith has 2, so none is measured yet.
The newest scored trade: bought $6,180 of IDN on Nov 25, 2025, filed Nov 25, 2025, scored 10 (weak). In the last 12 months: 1 buy worth $6,180 and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IDN: Intellicheck, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | IDNbuy Intellicheck, Inc. | $6,180 1,000 shares | +0% | - | |
| 10Weak | IDNbuy Intellicheck, Inc. | $9,327 2,500 shares | +1% | - | |
| 43Moderate | Intellicheck, Inc. | $1,670 1,000 shares | +0% | +4% from low-42% from high |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | IDN Intellicheck, Inc. | AGrant or award Common Stock, $.001 par value | +7,557 | $3.97 | $30k | 431,159 | Jul 17, 2026 |
| Mar 31, 2026 | IDN Intellicheck, Inc. | AGrant or award Common Stock, $.001 par value | +4,292 | $6.99 | $30k | 423,602 | Apr 6, 2026 |
| Jan 5, 2026 | IDN Intellicheck, Inc. | AGrant or award Restricted Stock Units (RSU's)derivative | +4,710 | $0.00 | $0 | 4,710 | Jan 7, 2026 |
| Nov 25, 2025 | IDN Intellicheck, Inc. | POpen-market purchase Common Stock, $.001 par value | +1,000 | $6.18 | $6,180 | 392,948 | Nov 25, 2025 |
| Sep 30, 2025 | IDN Intellicheck, Inc. | AGrant or award Restricted Stock Units (RSU's)derivative | +5,769 | $0.00 | $0 | 5,769 | Oct 2, 2025 |
| Jul 14, 2025 | IDN Intellicheck, Inc. | AGrant or award Restricted Stock Units (RSU's)derivative | +5,714 | $0.00 | $0 | 5,714 | Jul 15, 2025 |
| May 23, 2025 | IDN Intellicheck, Inc. | POpen-market purchase Common Stock, $.001 par value | +2,500 | $3.73 | $9,327 | 391,948 | May 23, 2025 |
| Apr 2, 2025 | IDN Intellicheck, Inc. | AGrant or award Restricted Stock Units (RSU's)derivative | +10,169 | $0.00 | $0 | 10,169 | Apr 3, 2025 |
| Dec 31, 2024 | IDN Intellicheck, Inc. | AGrant or award Restricted Stock Units (RSU's)derivative | +10,714 | $0.00 | $0 | 10,714 | Jan 3, 2025 |
| Dec 29, 2023 | IDN Intellicheck, Inc. | AGrant or award Restricted Stock Units (RSU's)derivative | +15,789 | $0.00 | $0 | 15,789 | Jan 2, 2024 |
| Nov 15, 2023 | IDN Intellicheck, Inc. | POpen-market purchase Common Stock, $.001 par value | +1,000 | $1.67 | $1,670 | 330,727 | Nov 15, 2023 |
Questions about Guy L Smith
Answered from the filings on this page, as of the latest one.
Is Guy L Smith buying or selling?
In the last 12 months Guy L Smith reported 1 open-market buy worth $6,180 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $6,180 of IDN on Nov 25, 2025. Grants, option exercises and tax withholding are not counted.
How did Guy L Smith's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Guy L Smith has 2.
Where does Guy L Smith file Form 4?
Guy L Smith has filed Form 4 at IDN (Intellicheck, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.